J Clin Endocrinol Metab. 2023 Feb 16:dgad079. doi: 10.1210/clinem/dgad079. Online ahead of print.
ABSTRACT
CONTEXT: Craniopharyngioma is a benign brain tumour with frequent local recurrence or progression after treatment. Growth hormone replacement therapy (GHRT) is prescribed in children with growth hormone deficiency due to childhood-onset craniopharyngioma.
OBJECTIVE: To evaluate whether shorter time delay of GHRT initiation after childhood-onset craniopharyngioma completion therapy increased the risk of new event (progression or recurrence).
METHODS: Retrospective, observational, monocenter study. We compared a cohort of 71 childhood-onset craniopharyngiomas all treated with recombinant human growth hormone (rhGH). Twenty-seven patients were treated with rhGH at least 12 months after craniopharyngioma treatment (“>12 months group”) and forty-four patients before 12 months (“<12 months group”) among which twenty-nine patients were treated between 6 and 12 months (“6-12 months group”). The main outcome was the risk of tumour new event (progression of residual tumour or tumour recurrence after complete resection) after primary treatment in the “>12 months” group and in the “<12 months” or in the “6-12 months” group patients.
RESULTS: In the “>12 months group”, the 2- and 5- years event-free survivals were respectively 81.5% (95% CI 61.1-91.9) and 69.4% (95% CI 47.9-83.4), as compared with 72.2% (95% CI 56.3-83.1) and 69.8% (95% CI 53.8-81.2) in the “<12 months” group. The 2- and 5- years event-free survivals were the same in the “6-12 months group” (72.4%, 95% CI 52.4-85.1). By Log-rank test, the event-free survival was not different between groups (p = 0,98 and p = 0,91).The median time for event was not statistically different.In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment.
CONCLUSIONS: No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumour progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas.
PMID:36794424 | DOI:10.1210/clinem/dgad079
